Spots Global Cancer Trial Database for Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Official Title: Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
Study ID: NCT00167999
Interventions
Study Description
Brief Summary: To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Detailed Description:
Keywords
Eligibility
Minimum Age: 15 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Seoul, , Korea, Republic of
Contact Details
Name: Medical Monitor
Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
